HOOKIPA Pharma Business Summary

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company that historically generated revenue through strategic licensing and collaboration agreements, most notably with Gilead Sciences and Roche. The company’s primary business segments focused on developing immunotherapies for infectious diseases and oncology using its proprietary arenavirus platform. However, as of February 2026, HOOKIPA has transitioned into a liquidation phase following the systematic divestment of its core pipeline. This includes the October 2025 completion of the sale of its HBV (HB-400) and HIV (HB-500) programs to Gilead Sciences and the February 2026 sale of its oncology assets, including HB-200 and HB-700, to NeoTrail Therapeutics. Currently trading on the OTC markets following its August 2025 delisting from the Nasdaq, the company operates as a liquidating entity. In the broader market, HOOKIPA previously competed with active immunotherapy developers such as BioNTech, Gritstone Bio, and PDS Biotech, but it now sits in a terminal positioning relative to these peers as it winds down operations to distribute remaining assets to stockholders. The leadership team is currently directed by Chief Executive Officer Dr. Malte Peters, who was appointed in July 2024 and previously served as the Chief Research and Development Officer at MorphoSys and a Vice President at Novartis Oncology. He is supported by Executive Vice President and CFO Terry Coelho, a seasoned executive with a pedigree that includes CFO roles at Gamida Cell and CinCor Pharma, as well as senior leadership at Novartis and Mars Incorporated. Technical operations are overseen by Chief Research & Development Officer Dr. Mark Winderlich, formerly an EVP at Evotec and a key drug development lead at MorphoSys. The company’s board is chaired by Julie O’Neill and includes notable members such as David R. Kaufman, M.D., Ph.D. Major institutional backing has historically come from investors such as JBF Capital, Inc. and Constellation Investments, Inc., who remain key stakeholders during the company’s dissolution process.